These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22012767)

  • 1. The influence of the genetic variant within miRNA-binding site in estrogen receptor alpha gene on the risk of breast cancer in postmenopausal women on hormone replacement therapy.
    Cerne JZ; Gersak K; Novakovic S
    Cancer Biomark; 2010-2011; 8(3):123-8. PubMed ID: 22012767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.
    Cerne JZ; Novakovic S; Frkovic-Grazio S; Pohar-Perme M; Stegel V; Gersak K
    Oncol Rep; 2011 Aug; 26(2):479-85. PubMed ID: 21567099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
    Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
    Cerne JZ; Stegel V; Gersak K; Novakovic S
    BMC Cancer; 2012 Mar; 12():105. PubMed ID: 22436609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between methylenetetrahydrofolate reductase genetic polymorphisms and postmenopausal breast cancer risk.
    Ziva Cerne J; Stegel V; Gersak K; Novakovic S
    Mol Med Rep; 2011; 4(1):175-9. PubMed ID: 21461582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women.
    Tchatchou S; Jung A; Hemminki K; Sutter C; Wappenschmidt B; Bugert P; Weber BH; Niederacher D; Arnold N; Varon-Mateeva R; Ditsch N; Meindl A; Schmutzler RK; Bartram CR; Burwinkel B
    Carcinogenesis; 2009 Jan; 30(1):59-64. PubMed ID: 19028706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.
    Chen Y; Gammon MD; Teitelbaum SL; Britton JA; Terry MB; Shantakumar S; Eng SM; Wang Q; Gurvich I; Neugut AI; Santella RM; Ahsan H
    Carcinogenesis; 2008 Apr; 29(4):766-71. PubMed ID: 18281250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.
    Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA
    Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of ESR1 rs2881766 increases breast cancer risk in Korean women.
    Son BH; Kim MK; Yun YM; Kim HJ; Yu JH; Ko BS; Kim H; Ahn SH
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):633-45. PubMed ID: 25323936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.
    Kotsopoulos J; Tworoger SS; De Vivo I; Hankinson SE; Hunter DJ; Willett WC; Chen WY
    Int J Cancer; 2009 Oct; 125(7):1685-91. PubMed ID: 19462450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women.
    Cerne JZ; Ferk P; Leskosek B; Gersak K
    Climacteric; 2011 Aug; 14(4):458-63. PubMed ID: 21294673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene.
    Cui Y; Shu XO; Cai Q; Jin F; Cheng JR; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1096-101. PubMed ID: 15894658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.
    Psaty BM; Smith NL; Lemaitre RN; Vos HL; Heckbert SR; LaCroix AZ; Rosendaal FR
    JAMA; 2001 Feb; 285(7):906-13. PubMed ID: 11180734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C genotype and established coronary artery disease.
    Emre A; Sahin S; Erzik C; Nurkalem Z; Oz D; Cirakoglu B; Yesilcimen K; Ersek B
    Cardiology; 2006; 106(1):44-50. PubMed ID: 16612068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of estrogen receptor-alpha gene polymorphism and hormone replacement therapy to fall risk and muscle strength in early postmenopausal women.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Partanen J; Mäenpää PH
    Ann Med; 2002; 34(1):64-72. PubMed ID: 12014437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
    Almeida S; Fiegenbaum M; de Andrade FM; Osório-Wender MC; Hutz MH
    Maturitas; 2006 May; 54(2):119-26. PubMed ID: 16242874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Int J Cancer; 2010 Jun; 126(12):2935-46. PubMed ID: 19739075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
    Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
    Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.